https://www.businesswire.com/news/home/20250602831213/en/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera ...
genomeclinicalperformancehighlightedasco